NeoGenomics Inc. Common Stock (NEO)
Stock · NASDAQ · Health Care
$16.66as of 10/16/2026
Price chart
Active signals
NEO Signal Track Record
How signals performed across all stocks →What NEO's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 34 | -3.4% | 44% | October 6, 2026 |
| Bollinger Band Breakout | 25 | +10.4% | 68% | September 17, 2026 |
| Bollinger Band Breakdown | 19 | -7.1% | 37% | October 6, 2026 |
| 200-Day Moving Average TouchActive now | 14 | -3.7% | 43% | May 27, 2026 |
| Any 20-session window (baseline) | +1.2% | 53% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About NEO
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in…
- Sector
- Health Care
- Industry
- Precision Instruments
- Employees
- 2,500
- Website
- neogenomics.com/
Fundamentals
- 1-day range
- $16.61$17.34
- Market cap
- $2.00B
- P/E (trailing)
- —
- P/E (forward)
- 50.33
- EPS (trailing)
- $-0.40
- Dividend yield
- —
- Beta
- 1.89
- Avg. volume
- 2.33M
How NeoGenomics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 17, 2026 · via SEC EDGAR / Finnhub
Forecasts
10 analyst ratings
NeoGenomics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- NEONeoGenomics Inc. Common Stock$16.65▼ 3.48%Market cap $2.00BP/E —$7.07$20.15
- ATRCAtriCure Inc. Common Stock$56.07▼ 2.96%Market cap $2.01BP/E 261.42$25.36$61.7
- MESOMesoblast Limited American Depositary Shares$13.28▼ 4.80%Market cap $2.02BP/E —$1.88$3.31
- AVAHAveanna Healthcare Holdings Inc. Common Stock$12.34▼ 2.37%Market cap $2.03BP/E 10.04$5.93$14.71
- ZBIOZenas BioPharma Inc. Common Stock$24.84▼ 2.20%Market cap $2.03BP/E —$13.5$44.6
- SGRYSurgery Partners Inc. Common Stock$14.61▼ 1.08%Market cap $1.95BP/E —$11.41$23.44
- STOKStoke Therapeutics Inc. Common Stock$24.17▼ 1.79%Market cap $2.06BP/E —$20.32$40.22
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| NEO NeoGenomics Inc. Common Stock | $2.00B | — | $16.65 | ▼ 3.48% | $7.07$20.15 |
| ATRC AtriCure Inc. Common Stock | $2.01B | 261.42 | $56.07 | ▼ 2.96% | $25.36$61.7 |
| MESO Mesoblast Limited American Depositary Shares | $2.02B | — | $13.28 | ▼ 4.80% | $1.88$3.31 |
| AVAH Aveanna Healthcare Holdings Inc. Common Stock | $2.03B | 10.04 | $12.34 | ▼ 2.37% | $5.93$14.71 |
| ZBIO Zenas BioPharma Inc. Common Stock | $2.03B | — | $24.84 | ▼ 2.20% | $13.5$44.6 |
| SGRY Surgery Partners Inc. Common Stock | $1.95B | — | $14.61 | ▼ 1.08% | $11.41$23.44 |
| STOK Stoke Therapeutics Inc. Common Stock | $2.06B | — | $24.17 | ▼ 1.79% | $20.32$40.22 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Why NeoGenomics (NEO) Stock Is Up TodayYahoo · 10/6/2026
- Stryker, Neogenomics Announce CEO Transitions; But One Stock DivesYahoo · 10/6/2026
- NeoGenomics Sinks 12% on CEO Succession Plan Despite Revenue BeatYahoo · 10/6/2026
- Did Strong Q3 Outlook and New CEO Plan Just Shift NeoGenomics' (NEO) Investment Narrative?Yahoo · 10/6/2026
- What's Going On With NeoGenomics Stock Tuesday?Benzinga · 10/6/2026
- This Boyd Gaming Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesdaybenzinga · 10/6/2026
- General Motors To Rally Around 40%? Here Are 10 Top Analyst Forecasts For TuesdayBenzinga · 10/6/2026
- StoneX Maintains Buy on NeoGenomics, Raises Price Target to $20Benzinga · 10/6/2026
- This Boyd Gaming Analyst Turns Bullish; Here Are Top 5 Upgrades For TuesdayBenzinga · 10/6/2026
Insider Activity
Insider Actions →- Warren Stone · October 1, 2026 · Option Exercise17.6K
- Warren Stone · October 1, 2026 · Tax Withholding6.9K
- Alicia C. Olivo · September 1, 2026 · Tax Withholding2.7K
- Warren Stone · August 21, 2026 · Option Exercise28.1K
- Warren Stone · August 21, 2026 · Tax Withholding11.1K
- Greg D. Aunan · August 4, 2026 · Sale20.0K @ $16.07
- Starrett Carolyn S · June 23, 2026 · Grant14.1K
- Starrett Carolyn S · June 23, 2026 · Grant9.8K
- Lynn A. Tetrault · June 15, 2026 · Sale5.3K @ $11.1
- Lynn A. Tetrault · June 9, 2026 · Sale5.3K @ $11.29
- Felicia Williams · June 1, 2026 · Grant16.0K
- Felicia Williams · June 1, 2026 · Grant11.1K
- Felicia Williams · June 1, 2026 · Option Exercise23.1K
- Lynn A. Tetrault · June 1, 2026 · Grant16.0K
- Lynn A. Tetrault · June 1, 2026 · Grant11.1K
Institutional Ownership
March 31, 2026
- Total shares held
- 125.75M
- Total value held
- $905.36M
- Institutional holders
- 248
- Unknown19.96M
- Unknown9.73M
- Unknown9.22M
- Unknown6.16M
- Unknown5.66M
- Unknown5.62M
- Unknown5.12M
- Unknown4.16M
- Unknown3.57M
- Unknown3.45M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
NeoGenomics Shares Drop 12% on CEO Transition News
NeoGenomics stock fell 12% following the announcement of a CEO succession plan, despite reporting a revenue beat and a strong Q3 outlook. The market reaction highlights how leadership changes can outweigh immediate financial results. Analysts remain mixed, with StoneX raising its price target to $20 while the average target sits at $21.55.
NeoGenomics Shares Drop 12% on CEO Transition News. NeoGenomics stock fell 12% following the announcement of a CEO succession plan, despite reporting a revenue beat and a strong Q3 outlook. The market reaction highlights how leadership changes can outweigh immediate financial results. Analysts remain mixed, with StoneX raising its price target to $20 while the average target sits at $21.55.